Updated:
BioSight
BioSight is a asset manager based in Herzliya; the Altss profile covers its classification, headquarters, registration, AUM band, and key contacts for...
BioSight
BioSight is a pharmaceutical development company, developing novel cancer-targeted drugs. BioSight
General information
Firm type
Asset Manager
Location
Region
Middle East
Country
Israel
City
Herzliya
Corporate office
Herzliya, Israel
Sector focus
Frequently asked questions
Are there other drugs in BioSight's pipeline?
No other drug candidates are disclosed on BioSight's website as of the latest available information. The firm's public corporate profile is built entirely around the advancement of BST-236, positioning it as a single-asset pharmaceutical developer.
Who founded BioSight, and who runs the company?
BioSight does not publicly identify its founders, management team, or board of directors on its primary website. The firm operates without a public-facing executive leadership page, making the identity of key investment and scientific decision-makers unavailable from primary sources.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: